Drug Trial Radar · NCT05123755
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Dec 20, 2021
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Vasomune Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).
Conditions
- Acute Respiratory Distress Syndrome
- Viral or Bacterial Infections
- Pneumonia
- Pneumonia, Viral
- Respiratory Infection
- COVID-19 Acute Respiratory Distress Syndrome
Interventions
AV-001 InjectionDrug
AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
AV-001 Placebo InjectionDrug
D-PBS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of multiple doses of IV administrations of AV-001 Injection compared with AV-001 placebo Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections.Time frame: Up to Day 60
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Denver Health Medical Center
Denver, Colorado
Northwestern University Medical Center
Chicago, Illinois
MedStar Health Research Institute, Inc.
Hyattsville, Maryland
Henry Ford Health System
Detroit, Michigan
The Ohio State University
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.